Dr. Morgenstern is a healthcare consultant and subject matter expert for Booz Allen Hamilton at the Walter Reed National Military Medical Center in Bethesda, MD. He is president of the Optometric Council on Refractive Technology.
After much anticipation and a long wait for both clinicians and patients in need, the U.S. Food and Drug Administration (FDA) approved corneal cross-linking (CXL) in mid April. This procedure is globally considered the only method of halting the progressive family of diseases called corneal ectasias, including keratoconus.
In a landmark paper titled “Global consensus on keratoconus and ectatic diseases” published in the April 2015 issue of Cornea, Gomes et al sought to reach a consensus of the definition, concepts, clinical management, and surgical treatments of keratoconus and the family of corneal ectatic diseases.